Merck (MRK) Exchange Rate Effect (2009 - 2026)
Merck's (MRK) quarterly Exchange Rate Effect came in at -$37.0 million in Q2 2026, down 109.89% year-over-year from $374.0 million in Q2 2025, and down 94.74% quarter-over-quarter from -$19.0 million in Q1 2026.
Analysis
Merck (MRK) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Exchange Rate Effect for 18 consecutive years, with -$37.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Exchange Rate Effect fell 109.89% year-over-year to -$37.0 million in Q2 2026; TTM through Jun 2026 was -$23.0 million, a 105.03% decrease from a year earlier, with the FY2025 full-year figure at $563.0 million, up 292.15% from the prior year.
- Exchange Rate Effect was -$37.0 million for Q2 2026 at Merck, down from -$19.0 million in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $374.0 million in Q2 2025 and troughed at -$412.0 million in Q3 2022.
- A 5-year average of -$9.6 million and a median of -$28.0 million in 2026 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 638.24% in 2022, down 795.65% in 2022.
- Over 5 years, Exchange Rate Effect stood at $366.0 million in 2022, then tumbled by 49.18% to $186.0 million in 2023, then tumbled by 297.31% to -$367.0 million in 2024, then soared by 106.27% to $23.0 million in 2025, then slumped by 260.87% to -$37.0 million in 2026.
- The last three Exchange Rate Effect figures came in at -$37.0 million (Q2 2026), -$19.0 million (Q1 2026), and $23.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.20 Bn | 622.44 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 448.14 Bn | 441.57 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 358.13 Bn | 350.98 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.12 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Pfizer | 156.55 Bn | 144.85 Bn | 10.94 Bn | -4.00 Mn |
| 6 | Sanofi | 52.17 Bn | 44.78 Bn | 10.79 Bn | 11.62 Mn |
| 7 | Revolution Medicines | 42.92 Bn | 42.92 Bn | - | - |
| 8 | Incyte | 24.72 Bn | 20.19 Bn | 1.57 Bn | -84,000.00 |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.83 Bn | 15.44 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 23.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 374.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Dec 31, 2024 | -367.00 Mn |
| Sep 30, 2024 | 294.00 Mn |
| Jun 30, 2024 | -82.00 Mn |
| Mar 31, 2024 | -138.00 Mn |
| Dec 31, 2023 | 186.00 Mn |
| Sep 30, 2023 | -157.00 Mn |
| Jun 30, 2023 | -93.00 Mn |
| Mar 31, 2023 | 87.00 Mn |
| Dec 31, 2022 | 366.00 Mn |
| Sep 30, 2022 | -412.00 Mn |
| Jun 30, 2022 | -309.00 Mn |
| Mar 31, 2022 | -55.00 Mn |
| Dec 31, 2021 | -68.00 Mn |
| Sep 30, 2021 | -46.00 Mn |